Abstract Not all biomarkers are equal, and some should not be termed biomarkers. Despite an explosion in putative biomarker discoveries from high-throughput proteomic technologies, very few advance beyond initial excitement to become validated, clinically actionable tools. Most stall in a “biomarker valley of death,” where promising signals fail to meet robust technical, scientific, and regulatory […]
A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-Busting with Unicorn Biomarkers.
July 25, 2026
J Hepatol